<DOC>
	<DOCNO>NCT00524342</DOCNO>
	<brief_summary>The purpose study determine efficacy safety rhIL-11 , give subcutaneously six consecutive month , reduce menstrual blood loss woman type 1 von Willebrand disease refractory menorrhagia . Efficacy measure subjective bleeding severity scale pictorial bleed chart . Safety measure frequency adverse event , include fever , headache , fatigue , myalgia , arthralgia , fluid retention , edema .</brief_summary>
	<brief_title>IL-11 Women With Von Willebrand Disease Refractory Menorrhagia</brief_title>
	<detailed_description>This study prospective , single-center Phase II trial Neumega ( rhIL-11 ) woman type 1 VWD menorrhagia refractory estrogen , hormone , hemostatic agent . It anticipate 10 subject meet eligibility criterion enroll complete study . All aspect study , include rhIL-11 injection screen , hemostatic safety monitoring , coagulation testing , consider experimental . The specific objective determine efficacy safety rhIL-11 reduce menstrual blood loss adult woman type 1 VWD six consecutive menstrual cycle , determine mechanism hemostatic response rhIL-11 .</detailed_description>
	<mesh_term>Menorrhagia</mesh_term>
	<mesh_term>Von Willebrand Diseases</mesh_term>
	<mesh_term>Oprelvekin</mesh_term>
	<criteria>Females 1845 year age Confirmed type 1 VWD , define low VWF : RCoF low VWF : Ag qualitatively normal VWF multimers Menorrhagia refractory estrogen , hormone , hemostatic agent Willingness blood drawn Use immunomodulatory experimental drug , diuretic Pregnant lactate woman unwilling use contraception study Previous cardiac disease , congestive failure , arrhythmia ( e.g. , atrial fibrillation , atrial flutter ) , hypertension , MI , stroke , thrombosis Past allergic reaction Neumega DDAVP Surgery within past 8 week Inability comply study protocol requirement Concomitant use antiplatelet drug , anticoagulant , dextran , aspirin NSAIDs Treatment DDAVP , cryoprecipitate , whole blood , plasma plasma derivative contain substantial quantity FVIII and/or VWF within five day study</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>IL-11</keyword>
	<keyword>von Willebrand disease</keyword>
	<keyword>von Willebrand factor</keyword>
	<keyword>VWFmRNA</keyword>
	<keyword>menorrhagia</keyword>
</DOC>